Status | Study |
Recruiting |
Study Name: Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Condition: Type 3 Choroidal Neovascularization Date: 2014-12-10 Interventions: Drug: Aflibercept |
Recruiting |
Study Name: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization Condition: Choroidal Neovascularization Date: 2014-10-06 Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) Administration by intravitreal injection |
Completed |
Study Name: OCT in Rare Chorioretinal Diseases Condition: Retinal Artery Occlusions Polypoidal Choroidal Vasculopathy Date: 2014-05-15 |
Completed |
Study Name: Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Condition: Uveitis Intermediate Uveitis Posterior Uveitis Date: 2013-02-05 Interventions: Drug: triamcinolone acetonide (Triesence®) 4 mg of TRIESENCE® (triamcinolone acetonide injecta |
Active, not recruiting |
Study Name: Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Condition: Intermediate Uveitis Posterior Uveitis Pan-uveitis Date: 2012-10-26 Interventions: Drug: Tocilizumab Tocilizumab (4 mg/kg or 8 mg/kg) O |
Active, not recruiting |
Study Name: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Condition: Posterior Uveitis Intermediate Uveitis Panuveitis Date: 2012-09-24 Interventions: Drug: FAI insert Drug: Sham injection |
Completed |
Study Name: Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Condition: Degeneration of Macula and Posterior Pole Date: 2012-08-16 Interventions: Biological: ranibizumab Interventional study, prospective |
Recruiting |
Study Name: Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Condition: Non-infectious Intermediate Uveitis Non-infectious Posterior Uveitis Date: 2012-02-01 Interventions: Drug: LFG316 LFG316 administer |
Recruiting |
Study Name: Intravitreal Sirolimus as Therapeutic Approach to Uveitis Condition: Uveitis Intermediate Uveitis Posterior Uveitis Date: 2011-01-20 Interventions: Drug: Intravitreal injection 440mcg |
Withdrawn |
Study Name: Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD Condition: Choroidal Neovascularization Myopia Punctate Inner Date: 2010-10-29 Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.) |